Eupraxia Pharmaceuticals, Inc. EPRX 深 沪
等待开盘 08-24 09:30:00 美东时间
6.73
-0.030
-0.44%
华盛通- 最 高6.875
- 今 开6.77
- 成交量 29.80万股
- 最 低 6.6788
- 昨 收 6.76
- 总市值 4.44亿
- 52周最高 9.32
- 市盈率 静 --
- 换手率 0.45%
- 52周最低 5.1501
- 委 比 -68.72%
- 总股本 6590.66万
- 历史最高 9.32
- 量 比 1.20
- 振 幅 2.90%
- 历史最低 2.20
- 每 手 1
- 风险率 0.97%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients
Eupraxia Pharmaceuticals Inc. announced positive results from the RESOLVE study, showing EP-104GI significantly reduces symptoms of odynophagia (pain swallowing) and dysphagia (difficulty swallowing) in EoE patients. Moderate to severe odynophagia dropped from 62% at baseline to 25% at 24-52 weeks, with no severe cases reported post-treatment. Similarly, moderate to severe dysphagia decreased from 77% to 25%. EP-104GI demonstrated good tolerabili...
08-13 12:00
Eupraxia Pharmaceuticals Q2 EPS $(0.23), Inline
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.23) per share which met the analyst consensus estimate. This is a 11.54 percent increase over losses of $(0.26) per share from the same period last year.
08-12 05:32
Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results
Eupraxia Pharmaceuticals Inc. announced its Q2 2026 financial results, reporting a net loss of $14.5 million, up from $8.7 million in Q2 2025, due to increased R&D and general expenses. The company highlighted positive data from its EP-104GI Phase 1b/2a trial in Eosinophilic Esophagitis (EoE), showing improvement in fibrosis and inflammation. Recent operational highlights include leadership appointments and the expansion of its EP-104GI target in...
08-11 21:21
美股大行评级 | 潜在涨幅90.66%！Tango Therapeutics获杰富瑞升目标价至60美元，上调至"买入"评级
今日重点评级关注：杰富瑞：上调Tango Therapeutics评级至"买入"，目标价从27美元升至60美元；Susquehanna：维持安森美半导体"积极"评级，目标价从120美元升至140美元
06-29 15:49
Oppenheimer Initiates Coverage On Eupraxia Pharmaceuticals with Outperform Rating, Announces Price Target of $17
Oppenheimer analyst Jay Olson initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Outperform rating and announces Price Target of $17.
06-26 21:12
Why JOYY Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Gainers: PHGE +97.3%, ARTL +74.8%, QTEX +52.4%, MNTX +34.4%, HLIT +28.3%, WOK +25%, CPSH +24.7%, CODX +22.7%, MDAI +22%. Losers: AKTX -25.2%, RYOJ -18.6%, DEVS -18.6%, AKAN -17%, ADTX -16.3%, LFS -15.6%
05-26 18:00
美股大行评级 | 英伟达绩后获11家大行集体上调目标价；劳氏、ELF、Intuit、VF等惨遭多家大行下调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx药业"超配"评级，目标价从84美元升至96美元；Ascendiant Capital：维持Liqtech国际"买入"评级，目标价从4.3美元升至4.4美元
05-22 10:18
Stifel Initiates Coverage On Eupraxia Pharmaceuticals with Buy Rating, Announces Price Target of $25
Stifel analyst Annabel Samimy initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy rating and announces Price Target of $25.
05-21 18:06
Eupraxia Pharmaceuticals Q1 EPS $(0.23) Misses $(0.22) Estimate
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.22) by 4.55 percent. This is a 9.52 percent decrease over losses of $(0.21) per
05-13 05:08
Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results
Eupraxia Pharmaceuticals Inc. reported positive clinical data and financial results for Q1 2026, highlighting significant progress in its EP-104GI treatment for Eosinophilic Esophagitis (EoE). The company completed a $63.2 million public offering to advance clinical trials and has sufficient cash reserves to fund operations into H2 2028. Recent highlights include near-complete tissue improvement in biopsy results and symptom data from the highest...
05-12 21:00
